Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Interleukin 15 (IL-15) is a pro-inflammatory cytokine involved in inflammatory diseases and IL-15 is expressed in atherosclerotic plaques.

Methods: To establish the role of IL-15 in atherosclerosis we studied the effect of IL-15 on atherosclerosis associated cells in vitro and in vivo by neutralizing IL-15 using a DNA vaccination strategy.

Results: Upon feeding a Western type diet LDLr(-/-) mice do express higher levels of IL-15 within the spleen and the number of IL-15 expressing cells among blood leukocytes and spleen cells is increased. Addition of IL-15 to macrophages induces the expression TNF-α and CCL-2. After the mice were vaccinated against IL-15, we observe a reduction in plaque size of 75% plaque. Unexpectedly, the relative number of macrophages within the plaque was 2-fold higher in IL-15 vaccinated mice than in control mice. Vaccination against IL-15 leads to an increased cytotoxicity against IL-15 overexpressing target cells, resulting in a reduction in IL-15 expressing cells and macrophages in blood and spleen and a decreased CD4/CD8 ratio.

Conclusion: Hypercholesterolemia leads to upregulation of IL-15 within spleen and blood. DNA vaccination against IL-15 does markedly reduces atherosclerotic lesion size, but does not promote lesion stability.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2010.11.037DOI Listing

Publication Analysis

Top Keywords

il-15
16
atherosclerotic lesion
8
il-15 atherosclerosis
8
dna vaccination
8
il-15 spleen
8
il-15 expressing
8
expressing cells
8
vaccination il-15
8
mice
5
cells
5

Similar Publications

Chimeric antigen receptor T-cell (CAR-T) therapies have demonstrated clinical efficacy in treating haematological malignancies, resulting in multiple regulatory approvals. However, there is a need for robust manufacturing platforms and the use of GMP-aligned reagents to meet the clinical and commercial demands. This study investigates the impact of serum/xeno-free medium (SXFM) and cytokine supplementation on CAR-T cell production in static and agitated culture systems, using 24-well plate G-Rex vessels and 500 mL stirred tank bioreactors (STRs), respectively.

View Article and Find Full Text PDF

Fatigue is a prevalent and debilitating symptom in rheumatic diseases such as rheumatoid arthritis and psoriatic arthritis. Despite advances in reducing inflammation through treatments, fatigue often persists, underscoring its multifactorial etiology. A possible link between the persistent inflammation observed in rheumatic diseases and the onset of fatigue has been suggested.

View Article and Find Full Text PDF

Photosensitivity is central to cutaneous lupus erythematosus (CLE) and dermatomyositis (DM), but the mechanisms linking UVB exposure to tissue-specific autoimmunity are poorly defined. Using single-cell RNA sequencing, spatial transcriptomics, UVB provocation, and in vitro modeling, we identify MMP9⁺ CD14⁺ myeloid cells as critical mediators of photosensitivity. These cells expand significantly in lesional skin, produce IFN-b, and colocalize with cytotoxic CD4⁺ T cells at the dermal-epidermal junction.

View Article and Find Full Text PDF

Interleukin 15 (IL15)-based near-infrared photoimmunotherapy.

Cancer Immunol Immunother

August 2025

Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.

Near-infrared photoimmunotherapy (NIR-PIT) is a highly selective cancer therapy based on a targeted monoclonal antibody conjugated to phthalocyanine-based photoabsorber, IRDye700DX (IR700). Following injection, near-infrared light activates the conjugate causing direct cytotoxicity and immunogenic cell death. The high selectivity of NIR-PIT is traditionally based on the binding of a monoclonal antibody to its target thus bringing the photoabsorber, IR700, in close proximity to the cell membrane at the time of light exposure.

View Article and Find Full Text PDF

Fast tumor-infiltrating lymphocytes (TILs): rapid manufacture of an adoptive cellular therapeutic from pleural infiltrating T cells for intrapleural administration.

Cytotherapy

August 2025

Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania, USA; Allegheny Health Network Research Institute, Pittsburgh, Pennsylvania, USA; Department of Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA. Electroni

Background Aims: Cancers of many different tissue origins can metastasize to the pleura, a space with a unique immune environment that predisposes to aggressive tumor behavior and the development of effusions, an exudative leakage of serous fluid accompanied by an immune infiltrate. Effusions are drained therapeutically to relieve dyspnea, often several times per week. Characteristically, they contain 50-1000 × 10 viable pleural T cells (PITs), which can be reliably activated and expanded in culture, making them an ideal source for generation of a cellular therapeutic.

View Article and Find Full Text PDF